<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 16, 2000
ViroPharma Incorporated
-----------------------
(Exact name of issuer as specified in charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-021699 23-2789550
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
</TABLE>
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
Item 5 - Other Events.
As is more fully described in the attached press release that is
incorporated herein by reference, on October 16, 2000, ViroPharma Incorporated
("ViroPharma") announced its initiation of human clinical trials with a new
antiviral compound for the treatment of respiratory syncytial virus disease.
This report, including the press release attached hereto, contains forward-
looking statements that involve a number of risks and uncertainties, including
those relating to the initiation of human clinical trials with ViroPharma's
product candidates for respiratory syncytial virus, the ability to deliver these
product candidates to the site of virus infection through certain inhalation
drug delivery technologies, the potential clinical benefit of these product
candidates and the estimated markets for respiratory syncytial virus. There
can be no assurance that planned clinical trials can be initiated on a timely
basis, or at all, or that such trials can be successfully concluded.
Investigational pharmaceutical products, such as ViroPharma's product candidates
for respiratory syncytial virus and inhalation drug delivery technologies,
require significant time and effort for research and development, laboratory
testing and clinical testing prior to regulatory approval and commercialization.
As a result, all of the activities described in this report, including the press
release attached hereto, are subject to risks and uncertainties. Neither the
FDA nor any other regulatory authority has approved any of ViroPharma's product
candidates for commercialization. There can be no assurance that FDA or other
regulatory authority approval for any product candidate under development by
ViroPharma will be granted on a timely basis or at all. Even if approved, there
can be no assurance that such drug candidates will achieve market acceptance.
These factors, and other factors that could cause future results to differ
materially from the expectations expressed in this report, including the press
release attached hereto, include, but are not limited to, those described in
ViroPharma's most recent Registration Statement on Form S-3 filed with the
Securities and Exchange Commission. The forward-looking statements contained in
this report, including the press release attached hereto, may become outdated
over time. ViroPharma does not assume any responsibility for updating any
forward-looking statements.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Press Release dated October 16,
2000
<PAGE>
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: October 16, 2000 By: /s/ Michel de Rosen
------------------------
Michel de Rosen
President and Chief Executive
Officer
<PAGE>
Index to Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Press Release dated October 16, 2000
